ICML 2021 | Evolution of eligibility criteria for DLBCL trials
Eliza Hawkes
• 9 Jun 2021
Eliza A. Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Centre, Melbourne, Australia, discusses the tightening of eligibility criteria for diffuse large B-cell lymphoma (DLBCL) randomized controlled trials over the past 30 years. In an analysis of 42 past and current DLBCL trials, an increase in the number and strictness of criteria was observed, translating into fewer patients with DLBCL being eligible for clinical trials today compared to 30 years ago. Fewer eligible patients may consequently produce clinical trial data that is not representative of the clinical population. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
